Skip to main content
. 2010 Jun;333(3):854–864. doi: 10.1124/jpet.109.165084

Fig. 6.

Fig. 6.

Effect of the competitive inhibitor verapamil (200 μM) on the permeability and P-gp-mediated efflux of PG 01037 across MDCK-MDR1 monolayers. A, P-gp expression levels over the period in which transport studies were conducted (passages 18–24). B, efflux ratios (mean ± S.D., n = 3) across MDCK-MDR1 monolayers in the absence (−) and presence (+) of verapamil. C, apical-to-basolateral permeability in the absence (−) and presence (+) of verapamil across MDCK-MDR1 monolayers (data represented as mean ± S.D., n = 3). *, p < 0.05.